Micro-pillar tunnel stamp for enhanced transdermal delivery of topical drug formulations
Source abstract
Abstract
Dissolving microneedles (DMNs), despite their minimally invasive drug administration, face challenges in skin insertion and drug-loading capacity, which lead to less effective drug delivery. The micro-pillar tunnel stamp (MPTS) was designed to enhance the transdermal delivery efficacy of externally provided topical formulations via the creation of microchannels. The tunnel and canal of the MPTS enable the simultaneous application of DMNs and topical drugs. The application of micro-pillar-polycaprolactone (MP-PCL), which is a DMN made of a slowly dissolving polymer, exhibited a drug permeation rate 1.3-fold and 2.6-fold higher than that of micro-pillar-hyaluronic acid (MP-HA), a DMN made of a rapidly dissolving polymer, and the topical group, respectively. The base diameter of MP-PCL was set to 700 μm for maximized delivery efficacy, achieving 2.8-fold higher L-ascorbic acid accumulation than that of the topical group. In vivo analysis showed that, compared to topical administration, MPTS-delivered lidocaine had 5-fold greater permeation and the MPTS-delivered group showed 1.25-fold higher skin residual amount, confirming enhanced delivery. Thus, the optimized MPTS system can be presented as an attractive alternative to overcome the limitations of the existing MN systems such as incomplete insertion and limited drug-loading capacity, enhancing the delivery of topical formulations in the transdermal market. STATEMENT OF SIGNIFICANCE: We developed a micro-pillar tunnel stamp (MPTS) to enhance the delivery of externally provided topical formulations. The functional tunnel and canal of the MPTS enabled the simultaneous application of a dissolving microneedle (DMN) array insertion and administration of external topical drugs. Upon insertion, the DMNs created skin microchannels that allowed the externally administered drug to diffuse. DMNs were fabricated using polycaprolactone (PCL), a slowly dissolving polymer, to maintain their structure inside the skin and prolong the opening duration of the microchannels. This system achieved significantly improved delivery of topically administered external drugs via integration with slowly dissolving DMNs, while offering the possibility of its development as a universal delivery system for various topical pharmaceuticals.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Dermatology and Skin Diseases · Bee Products Chemical Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (53)
Show source-provided references
1. Transdermal patches: history, development and pharmacology10.1111/bph.13059 ↗
2. Recent advances in transdermal drug delivery systems: a review
3. Transdermal drug delivery10.1038/nbt.1504 ↗
4. Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations10.1016/S0168-3659(98)00187-4 ↗
5. The 500 Dalton rule for the skin penetration of chemical compounds and drugs10.1034/j.1600-0625.2000.009003165.x ↗
6. Transdermal delivery for gene therapy10.1007/s13346-022-01138-1 ↗
7. Microneedles: A smart approach and increasing potential for transdermal drug delivery system10.1016/j.biopha.2018.10.078 ↗
8. Microneedles in diagnostic, treatment and theranostics: an advancement in minimally-invasive delivery system
9. Minimally invasive protein delivery with rapidly dissolving polymer microneedles10.1002/adma.200701205 ↗
10. Microneedle patches for vaccination in developing countries10.1016/j.jconrel.2015.11.019 ↗
11. Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum10.3390/pharmaceutics7040438 ↗
12. Transdermal delivery of drugs with microneedles-potential and challenges10.3390/pharmaceutics7030090 ↗
13. Design and development of liquid drug reservoirs for microneedle delivery of poorly soluble drug molecules
14. Comprehensive review of microneedles: types, materials, processes, characterizations and applications
15. Hydrogel-forming microneedle arrays exhibit antimicrobial properties: potential for enhanced patient safety10.1016/j.ijpharm.2013.04.045 ↗
16. Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery10.1002/adfm.201200864 ↗
17. Hydrogel-forming microneedles: current advancements and future trends10.1002/mabi.202000307 ↗
18. A swellable microneedle patch to rapidly extract skin interstitial fluid for timely metabolic advances10.1002/adma.201702243 ↗
19. Microfabricated microneedles: a novel approach to transdermal drug delivery10.1021/js980042+ ↗
20. Characterization of microchannels created by metal microneedles: formation and closure10.1208/s12248-011-9288-3 ↗
21. Skin microporation: strategies to enhance and expand transdermal drug10.1016/S1773-2247(14)50048-2 ↗
22. Enhanced transdermal delivery by combined application of dissolving microneedle patch on serum-treated skin10.1021/acs.molpharmaceut.7b00111 ↗
23. Two-phase delivery using a horse oil and adenosine-loaded dissolving microneedle patch for skin barrier restoration, moisturization, and wrinkle improvement10.1111/jocd.12768 ↗
24. A patchless dissolving microneedle delivery system enabling rapid and efficient transdermal drug delivery
25. Diclofenac enables unprecedented week-long microneedle-enhanced delivery of a skin impermeable medication in humans10.1007/s11095-013-1036-1 ↗
26. Micropore closure rates following microneedle application at various anatomical sites in healthy human subjects10.1159/000515454 ↗
27. Kinetics of skin resealing after insertion of microneedles in human subjects10.1016/j.jconrel.2011.05.021 ↗
28. Centrifugal lithography: self-shaping of polymer microstructures encapsulating biopharmaceutics by centrifuging polymer drops10.1002/adhm.201700326 ↗
29. Materials used to simulate physical properties of human skin10.1111/srt.12235 ↗
30. Pharmacokinetics of a Lidocaine Patch 5% in Dogs10.1111/j.1439-0442.2006.00778.x ↗
31. The development and characteristics of novel microneedle arrays fabricated from hyaluronic acid, and their application in the transdermal delivery of insulin10.1016/j.jconrel.2012.05.030 ↗
32. Biocompatibility and biodegradation of polycaprolactone-sebacic acid blended gels10.1002/jbm.a.33272 ↗
33. The application of polycaprolactone in three-dimensional printing scaffolds for bone tissue engineering
34. Solvent-free polycaprolactone dissolving microneedles generated via the thermal melting method for the sustained release of capsaicin
35. Current advances in the fabrication of microneedles for transdermal delivery10.1016/j.jconrel.2014.04.052 ↗
36. In-situ re-melting and re-solidification treatment of selective laser sintered polycaprolactone lattice scaffolds for improved filament quality and mechanical properties10.1088/1758-5090/ab860e ↗
37. Synthesis of polycaprolactone: a review10.1039/b820162p ↗
38. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery10.1016/j.jconrel.2005.02.002 ↗
39. Microneedling for acne scars in Asian skin type: an effective low cost treatment modality10.1111/jocd.12095 ↗
40. Optical coherence tomography is a valuable tool in the study of the effects of microneedle geometry on skin penetration characteristics and in-skin dissolution10.1016/j.jconrel.2010.08.008 ↗
41. Hyaluronan molecular weight: effects on dissolution time of dissolving microneedles in the skin and on immunogenicity of antigen
42. Shape of dissolving microneedles determines skin penetration ability and efficacy of drug delivery
43. Micro-pillar integrated dissolving microneedles for enhanced transdermal drug delivery
44. Systematic comparisons of dissolving and swelling hyaluronic acid microneedles in transdermal drug delivery10.1016/j.ijbiomac.2021.09.161 ↗
45. On the stability of ascorbic acid in emulsified systems for topical and cosmetic use10.1016/S0378-5173(99)00228-8 ↗
46. Lidocaine and bupivacaine as part of multimodal pain management in a C57BL/6J laparotomy mouse model
47. Comparison of skin anesthetic effect of liposomal lidocaine, nonliposomal lidocaine, and EMLA using 30-minute application time10.1111/j.1524-4725.1998.tb04203.x ↗
48. Maximum recommended doses of local anesthetics: a multifactorial concept
49. A proposed model membrane and test method for microneedle insertion studies10.1016/j.ijpharm.2014.05.042 ↗
50. Microneedles with controlled bubble sizes and drug distributions for efficient transdermal drug delivery
51. Allometric scaling of skin thickness, elasticity, viscoelasticity to mass for micro-medical device translation: from mice, rats, rabbits, pigs to humans
52. Skin wound healing in humans and mice: challenges in translational research10.1016/j.jdermsci.2017.12.009 ↗
53. Mouse models of psoriasis10.1038/sj.jid.5700807 ↗